Treatment with cancer peptide vaccine cocktail derived from URLC10, KIF20A, VEGFR-1 and VEGFR-2 for the patients with advanced or recurrent esophageal cancer refractory to the standerd tharapy - Treatment with cancer peptide vaccine cocktail for the patients with advanced or recurrent esophageal cancer refractory to the standerd tharapy

Wakayama Medical University0 个研究点目标入组 40 人开始时间: 2014年4月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who received all peptides derived from VEGFR-1, VEGFR-2, URLC10 and KIF20A. Patients with other malignant tumor except for mucosal lesion. Primary tumor is widely invaded to other organs and is strongly concerned to bleed. History or intercurrent illness of intestinal pneumonia or pulmonary fibrosis. Symptomatic CNS metastasis. Patients with pleural effusion, abdominal effusion or pericardial effusion requiring a puncture or drainage. Severe infection or suspicious of severe infection. Severe mental disorder or severe neurological disorder. Uncontrolled heart, lung, kidney, or liver disease. Other uncontrolled intercurrent illness. Previous history of myocardial infarction, severe unstable angina, CABG surgery, congestive heart failure, cerebrovascular disease, pulmonary embolism, deep vein thrombosis or any other serious thromboembolism within 12 months prior to drug administration. Uncured traumatic injury (including traumatic bone fracture). Bleeding diathesis (including the fatal aneurysm) or coagulopathy. Continuous administration of antithrombotic drugs except for aspirin. Treatment-resistant hypertension. Heart failure under treatment. Patients receiving other investigational agents. Women who are breast-feeding or pregnant. Patients without intention to contraception. Patients who are judged as ineligible to attend study by investigator.

发起方